Trial Profile
A Study to Evaluate the Efficacy and Safety of Neoadjuvant Nab-Paclitaxel and Gemcitabine in Patients With Borderline Resectable or Unresectable Locally Advanced Pancreatic Adenocarcinoma Who were Ineligible for FOLFIRINOX Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Apr 2016
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 04 Apr 2016 New trial record